HC Wainwright Brokers Increase Earnings Estimates for FENC

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Research analysts at HC Wainwright increased their Q2 2025 earnings estimates for Fennec Pharmaceuticals in a research note issued on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.07) per share for the quarter, up from their previous forecast of ($0.10). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.14) EPS, Q1 2026 earnings at $0.06 EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.19 EPS and Q4 2026 earnings at $0.26 EPS.

Several other brokerages also recently issued reports on FENC. Craig Hallum upped their price objective on shares of Fennec Pharmaceuticals from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, May 14th. Wedbush reaffirmed an “outperform” rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Monday, March 10th.

Fennec Pharmaceuticals Stock Performance

Shares of FENC opened at $7.97 on Thursday. The company has a market capitalization of $220.12 million, a price-to-earnings ratio of -79.69 and a beta of 0.32. The company’s 50 day simple moving average is $6.04 and its 200 day simple moving average is $6.02. Fennec Pharmaceuticals has a 1 year low of $3.96 and a 1 year high of $8.56.

Fennec Pharmaceuticals (NASDAQ:FENC) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.08. The business had revenue of $8.51 million for the quarter, compared to the consensus estimate of $8.18 million. Fennec Pharmaceuticals had a negative net margin of 2.30% and a negative return on equity of 53.38%. During the same quarter in the prior year, the firm posted $0.41 earnings per share.

Institutional Trading of Fennec Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in shares of Fennec Pharmaceuticals in the 1st quarter worth approximately $90,000. AQR Capital Management LLC acquired a new position in shares of Fennec Pharmaceuticals in the 1st quarter worth approximately $66,000. Nuveen LLC acquired a new position in shares of Fennec Pharmaceuticals in the 1st quarter worth approximately $158,000. AIGH Capital Management LLC acquired a new position in shares of Fennec Pharmaceuticals in the 1st quarter worth approximately $2,199,000. Finally, Pinnacle Wealth Planning Services Inc. acquired a new position in shares of Fennec Pharmaceuticals in the 4th quarter worth approximately $97,000. 55.51% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Fennec Pharmaceuticals news, CEO Jeffrey S. Hackman purchased 13,965 shares of Fennec Pharmaceuticals stock in a transaction dated Monday, May 19th. The shares were bought at an average cost of $6.99 per share, for a total transaction of $97,615.35. Following the transaction, the chief executive officer now owns 15,000 shares in the company, valued at $104,850. This represents a 1,349.28% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $5.25, for a total transaction of $52,500.00. Following the completion of the sale, the director now owns 61,156 shares in the company, valued at approximately $321,069. This represents a 14.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,000 shares of company stock valued at $183,500 in the last ninety days. Corporate insiders own 11.76% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.